Post by Novotech

We’re pleased to announce that Dylan Matzinger has joined Novotech as Chief Business Officer, strengthening our Executive Leadership Team. Dylan brings nearly 20 years of experience across clinical research, biopharma, and global commercial operations, with a strong track record of building high-performing teams and driving commercial growth. Dylan’s industry expertise and leadership will support Novotech’s continued global expansion and commitment to advancing innovative therapies. We’re excited to welcome Dylan to the team.